PFG Advisors lifted its stake in Pfizer Inc. (NYSE:PFE) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,182 shares of the biopharmaceutical company’s stock after purchasing an additional 451 shares during the quarter. PFG Advisors’ holdings in Pfizer were worth $866,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Eagle Capital Management LLC raised its position in shares of Pfizer by 1.3% in the 2nd quarter. Eagle Capital Management LLC now owns 84,677 shares of the biopharmaceutical company’s stock worth $3,668,000 after purchasing an additional 1,125 shares during the last quarter. Kanawha Capital Management LLC raised its position in shares of Pfizer by 3.0% in the 2nd quarter. Kanawha Capital Management LLC now owns 188,839 shares of the biopharmaceutical company’s stock worth $8,180,000 after purchasing an additional 5,475 shares during the last quarter. Johnson Investment Counsel Inc. raised its position in shares of Pfizer by 0.5% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 160,772 shares of the biopharmaceutical company’s stock worth $6,964,000 after purchasing an additional 773 shares during the last quarter. ETF Managers Group LLC purchased a new position in shares of Pfizer in the 2nd quarter worth about $193,000. Finally, SRB Corp purchased a new position in shares of Pfizer in the 2nd quarter worth about $490,000. 70.21% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently issued reports on PFE shares. Royal Bank of Canada started coverage on Pfizer in a research report on Monday, January 6th. They issued an “outperform” rating and a $46.00 price target for the company. Bank of America initiated coverage on Pfizer in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price for the company. Credit Suisse Group reissued a “hold” rating and issued a $41.30 target price on shares of Pfizer in a research report on Wednesday, November 6th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Finally, ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Nine analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $43.41.
Shares of NYSE:PFE opened at $40.07 on Wednesday. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $44.56. The business has a 50-day simple moving average of $38.85 and a two-hundred day simple moving average of $38.20. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.68 and a current ratio of 0.90. The firm has a market cap of $218.54 billion, a price-to-earnings ratio of 13.36, a price-to-earnings-growth ratio of 4.18 and a beta of 0.65.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The business had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. During the same quarter in the previous year, the firm earned $0.78 EPS. Pfizer’s revenue was down 4.6% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.97 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be given a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, January 30th. This represents a $1.52 annualized dividend and a dividend yield of 3.79%. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. Pfizer’s dividend payout ratio is presently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Pattern Day Trader
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.